Authors: Pamela Horsley Judith D Bauer Rachael Mazkowiack Raeina Gardner John Bashford
Publish Date: 2006/08/03
Volume: 15, Issue: 1, Pages: 105-109
Abstract
The aim of this study was to compare palifermin a recombinant form of human keratinocyte growth factor with standard treatment on outcomes in patients receiving a high dose of chemotherapy conditioning regimen undergoing hematopoietic stem cell transplantation HSCTOver a 1year period a series of 59 patients were included 32 patients palifermin were compared with 27 patients standard treatment Outcomes assessed at day 8 posttransplantation were mucositis swallowing nutrition impact symptoms dietary intake time to engraftment length of stay infection and cumulative dose and duration of narcotic administrationThere was a significant reduction in the incidence of severe oral mucositis 13 vs 48 p=0003 swallowing problems p=0044 number of nutrition impact symptoms experienced 49 vs 60 p=0003 and length of stay 14 vs 18 days p=0026 in the palifermin group compared to standard care There was no significant difference in infection dietary intake time to engraftment or cumulative dose and duration of narcotic administration between groups
Keywords: